Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic ImpairmentJohn P. Gibbs, Maurice G. Emery, J. Greg Slatter et al.|The Journal of Clinical Pharmacology|2016Cited by 25
1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)Anthony J. Olszanski, Xīn Gào, Sandip Pravin Patel et al.|Annals of Oncology|2023Cited by 14
A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.Gerald S. Falchook, Anthony J. Olszanski, Jason J. Luke et al.|Journal of Clinical Oncology|2021Cited by 10